KHPG(SZ:002773)2022-11-22 03:01Group 1: R&D Progress and Pipeline - The company has a diverse pipeline focusing on small molecule drugs, biologics, gene therapy, and antibody development, with several projects in various stages of development [2][3]. - The small molecule drug KH617 for glioma has applied for PCT patent and is undergoing GLP safety evaluation, with clinical trial applications being prepared for submission in both China and the US [2]. - The KH629 project for treating NASH is progressing normally, and multiple projects utilizing AI technology and special formulations have transitioned from R&D to development stages [3]. Group 2: Clinical Trials and Innovations - The company aims to introduce one original Class 1 new product into clinical trials each year over the next three years [3]. - The antibody project KH906 for treating ocular neovascularization is about to enter Phase II clinical trials, while KH903 for gastric and colorectal cancer is nearing completion of Phase II trials [3]. - The company is developing an AAV delivery system for gene therapy, with products like KH631 showing sustained efficacy in preclinical models and expected to submit clinical trial applications by the end of 2021 or early 2022 [3]. Group 3: Clinical Trial Challenges - The global Phase III clinical trial of Conbercept faced setbacks, with preliminary data analysis ongoing and further investigation required to understand the results [4]. - The company is reconsidering the future plans for its Beijing factory due to the termination of the overseas clinical trial, although the factory is expected to play a significant role in the future of biopharmaceuticals [4]. Group 4: Financial Overview - As of the end of 2020, the company reported cumulative development expenses of 139,692.30 million yuan, which were expensed in the current period [4]. - The company has not yet predicted the expenses related to the halted PANDA trial for 2021 [5].